Foundations Investment Advisors LLC Purchases 7,603 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Foundations Investment Advisors LLC increased its Gilead Sciences stake by 8.3% in the fourth quarter, buying 7,603 additional shares and bringing its total holding to 98,745 shares worth about $12.1 million.
• Institutional ownership in Gilead remains heavy, with firms like Vanguard, Invesco, and Legal & General also boosting positions; overall, 83.67% of the stock is owned by institutional investors.
• Analysts remain broadly positive after Gilead beat quarterly EPS and revenue estimates, while the company also announced a $0.82 quarterly dividend and disclosed recent insider share sales by its CFO and CEO.

Foundations Investment Advisors LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 98,745 shares of the biopharmaceutical company's stock after buying an additional 7,603 shares during the quarter. Foundations Investment Advisors LLC's holdings in Gilead Sciences were worth $12,120,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company's stock valued at $14,863,487,000 after buying an additional 2,113,692 shares during the period. Invesco Ltd. lifted its holdings in shares of Gilead Sciences by 12.0% during the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company's stock valued at $1,680,505,000 after buying an additional 1,618,453 shares during the period. Legal & General Group Plc lifted its holdings in shares of Gilead Sciences by 1.0% during the 4th quarter. Legal & General Group Plc now owns 10,317,613 shares of the biopharmaceutical company's stock valued at $1,266,384,000 after buying an additional 107,014 shares during the period. Ameriprise Financial Inc. increased its holdings in Gilead Sciences by 5.9% during the third quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company's stock valued at $793,506,000 after buying an additional 400,002 shares during the last quarter. Finally, Nordea Investment Management AB raised its position in Gilead Sciences by 16.5% in the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company's stock worth $630,056,000 after acquiring an additional 726,101 shares during the period. 83.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on GILD. Mizuho increased their price target on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 18th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a "buy" rating in a research report on Wednesday, February 11th. Barclays began coverage on shares of Gilead Sciences in a research report on Friday, February 20th. They issued an "equal weight" rating and a $155.00 price target on the stock. Truist Financial reiterated a "buy" rating and issued a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $170.00 price target on shares of Gilead Sciences in a research report on Monday, February 23rd. Twenty-five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $156.93.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the sale, the chief financial officer directly owned 173,191 shares of the company's stock, valued at $22,907,973.57. This represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the sale, the chief executive officer directly owned 632,567 shares of the company's stock, valued at approximately $81,702,353.72. This trade represents a 1.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 53,000 shares of company stock valued at $7,075,670 over the last three months. Corporate insiders own 0.30% of the company's stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $136.22 on Friday. The firm has a fifty day moving average price of $135.43 and a 200-day moving average price of $134.08. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The stock has a market cap of $169.13 billion, a PE ratio of 18.56 and a beta of 0.31. Gilead Sciences, Inc. has a 1 year low of $104.46 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analysts' expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company's revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. Gilead Sciences's dividend payout ratio is 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.